Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 5/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 4/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 1.00 |
| ▸ | KCNK2 | O95069 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | CACNA1C | Q13936 | 2/20 | 1.00 |
| ▸ | SLC7A5 | Q01650 | 7/20 | 0.82 |
| ▸ | MEN1 | O00255 | 4/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.68 |
| ▸ | LMNA | P02545 | 4/20 | 0.68 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.68 |
| ▸ | NPC1 | O15118 | 2/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.68 |
| ▸ | MTOR | P42345 | 2/20 | 0.68 |
| ▸ | RAB9A | P51151 | 2/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.68 |
| ▸ | HTR2C | P28335 | 2/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.68 |
| ▸ | TP53 | P04637 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Seproxetine SCHEMBL272873 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3KCNK2KCNH2 | |
| Norfluoxetine SCHEMBL3750512 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3KCNK2KCNH2 | |
| Norfluoxetine SCHEMBL140929 | 0.98 | SLC6A4 (0.97) | SLC6A4SLC6A2SLC6A3KCNK2KCNH2 | |
| Seproxetine SCHEMBL120303 | 0.98 | SLC6A4 (0.97) | SLC6A4SLC6A2SLC6A3KCNK2KCNH2 | |
| Norfluoxetine SCHEMBL7306073 | 0.93 | SLC6A4 (0.87) | SLC6A4SLC6A2SLC6A3KCNK2KCNH2 | |
| SCHEMBL17267513 | 0.90 | SLC7A5 (1.00) | SLC6A4SLC6A2SLC6A3KCNK2KCNH2 | |
| SCHEMBL17267476 | 0.90 | SLC7A5 (1.00) | SLC6A4SLC6A2SLC6A3KCNK2KCNH2 | |
| SCHEMBL17267474 | 0.90 | SLC7A5 (1.00) | SLC6A4SLC6A2SLC6A3KCNK2KCNH2 | |
| SCHEMBL17267515 | 0.89 | SLC7A5 (1.00) | SLC6A4SLC6A2SLC6A3KCNK2KCNH2 | |
| SCHEMBL2738930 | 0.88 | SLC6A4 (0.78) | SLC6A4SLC6A2SLC6A3KCNK2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3787631-B1 | MODULATORS OF ORPHAN NUCLEAR RECEPTORS FOR NASH AND OTHER METABOLIC DISORDERS | UNIV EMORY (US) | 2025-09-10 | — | — | EP | claimed |
| EP-3603674-B1 | COMBINATION OF MORPHINAN COMPOUNDS AND ANTIDEPRESSANT FOR THE TREATMENT OF INTRACTABLE AND CHRONIC PAIN | SUN PHARMACEUTICAL IND INC (US) | 2025-02-26 | — | — | EP | claimed |
| US-7485754-B2 | Efficient method for preparing 3-aryloxy-3-arylpropylamines and their optical stereoisomers | APOTEX PHARMACHEM INC. (CA) | 2009-02-03 | — | — | US | claimed |
| WO-2007006132-A1 | AN EFFICIENT METHOD FOR PREPARING 3-ARYLOXY-3- ARYLPROPYLAMINES AND THEIR OPTICAL STEREOISOMERS | APOTEX PHARMACHEM INC. (CA) | 2007-01-18 | — | — | WO | claimed |
| US-20070010678-A1 | Efficient method for preparing 3-aryloxy-3-arylpropylamines and their optical stereoisomers | APOTEX PHARMACHEM INC. | 2007-01-11 | — | — | US | claimed |
| US-20040266882-A1 | Aryloxypropylamines as chemosensitizing agents in the treatment of cancer | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2004-12-30 | — | — | US | claimed |
| EP-1425002-A1 | ARYLOXYPROPYLAMINES AS CHEMOSENSITIZING AGENTS IN THE TREATMENT OF CANCER | Ramot at Tel Aviv University Ltd. (IL) | 2004-06-09 | — | — | EP | claimed |
| US-20040054014-A1 | Method and pharmaceutical compositions forthe treatment of cancer | RAMOT AT TEL AVIV UNIVERSITY LTD. | 2004-03-18 | — | — | US | claimed |
| US-6630454-B2 | Method and pharmaceutical composition for the treatment of cancer | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2003-10-07 | — | — | US | claimed |
| US-20030087964-A1 | Method and pharmaceutical composition for the treatment of cancer | RAMOT UNIVERSITY AUTHORITY FOR APPLIED RESEARCH AND INDUSTRIAL DEVELOPMENT LTD. | 2003-05-08 | — | — | US | claimed |
| EP-0831799-B1 | COMPOUNDS ACTIVE AT A NOVEL SITE ON RECEPTOR-OPERATED CALCIUM CHANNELS USEFUL FOR TREATMENT OF NEUROLOGICAL DISORDERS | NPS PHARMA INC (US) | 2003-05-02 | — | — | EP | claimed |
| WO-2003022258-A1 | ARYLOXYPROPYLAMINES AS CHEMOSENSITIZING AGENT IN THE TREATMENT OF CANCER | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2003-03-20 | — | — | WO | claimed |
| EP-0969874-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING PROPANAMINE DERIVATIVES AND CYCLODEXTRIN | Therabel Industries S.A. (FR) | 2000-01-12 | — | — | EP | claimed |
| WO-1998042382-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING PROPANAMINE DERIVATIVES AND CYCLODEXTRIN | THERABEL INDUSTRIES S.A. (FR) | 1998-10-01 | — | — | WO | claimed |
| US-4313896-A | ANTIDEPRESSANTS, PSYCHOTROPIC AGENTS | ELI LILLY AND COMPANY (US) | 1982-02-02 | — | — | US | claimed |
| US-4314081-A | ANTIDEPRESSANTS | ELI LILLY AND COMPANY (US) | 1982-02-02 | — | — | US | claimed |
| CN-116283626-B | Fluoxetine hapten, monoclonal antibody, hybridoma cell strain and application | 江南大学 | 2024-12-06 | — | — | CN | disclosed |
| CN-118858475-A | Detection reagent, detection kit and application thereof in psychotropic drug detection | 广州凯普医学检验所有限公司 | 2024-10-29 | — | — | CN | disclosed |
| US-4194009-A | ANTIDEPRESSANT | ELI LILLY AND COMPANY (US) | 1980-03-18 | — | — | US | disclosed |
| US-4018895-A | Aryloxyphenylpropylamines in treating depression | ELI LILLY AND COMPANY (US) | 1977-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040054014-A1 | Method and pharmaceutical compositions forthe treatment of cancer | ABCC1, ABCB1, SLC11A2 | SLC6A4 340/4885SLC6A2 374/4885SLC6A3 334/4885 |
| US-20030087964-A1 | Method and pharmaceutical composition for the treatment of cancer | PNMT, ABCC1, HNMT | SLC6A4 596/4885SLC6A2 550/4885SLC6A3 606/4885 |
| US-20040266882-A1 | Aryloxypropylamines as chemosensitizing agents in the treatment of cancer | ABCC1, PNMT, ABCB1 | SLC6A4 280/4885SLC6A2 290/4885SLC6A3 272/4885 |
| US-20070010678-A1 | Efficient method for preparing 3-aryloxy-3-arylpropylamines and their optical stereoisomers | SLC6A4, HTR3A, TPH2 | SLC6A4 1/4885SLC6A2 13/4885SLC6A3 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.